The Role of Statins on Helicobacter pylori Eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg)
María Caldas, Ángeles Pérez‐Aísa, Bojan Tepeš, Alma Keco‐Huerga, Luís Bujanda, Alfredo J. Lucendo, Luı́s Rodrigo, Dino Vaira, Luis Fernández‐Salazar, José María Huguet, Jorge Pérez-Lasala, Nataša Brglez Jurečič, Galina Fadeenko, Jésus Barrio, Miguel Areia, Juan Ortuño, Rinaldo Pellicano, Mārcis Leja, Javier Molina‐Infante, Pavel Bogomolov, С. А. Алексеенко, Manuel Domínguez‐Cajal, Judith Gómez‐Camarero, Vassiliki Ntouli, Samuel J. Martínez‐Domínguez, Rafael Ruiz-Zorrilla, Óscar Núñez, А. С. Сарсенбаева, Pedro Almela, Perminder Phull, Marta Espada, Ignasi Puig, Olga P. Nyssen, Françis Mégraud, C O'Morain, Javier P. Gisbert, on behalf of the Hp-EuReg Investigators
Abstract
Statins could increase the effectiveness of Helicobacter pylori eradication therapies due to their anti-inflammatory effect. The aim of this study was to analyze the impact of this therapeutic association in real life. This is a multicenter, prospective, non-interventional study aimed at evaluating the management of H. pylori by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap from 2013 to 2020. The association between statin use and H. pylori eradication effectiveness was evaluated through multivariate analysis. Overall, 9988 and 705 patients received empirical and culture-guided treatment, respectively. Overall, statin use was associated with higher effectiveness in the empirical group (OR = 1.3; 95%CI = 1.1–1.5), but no association was found with first-line treatment effectiveness (N = 7738); as an exception, statin use was specifically associated with lower effectiveness of standard triple therapy (OR = 0.76; 95%CI = 0.59–0.99). In the rescue therapy empirical group (N = 2228), statins were associated with higher overall effectiveness (OR = 1.9; 95%CI = 1.4–2.6). However, sub-analyses by treatment schemes only confirmed this association for the single-capsule bismuth quadruple therapy (OR = 2.8; 95%CI = 1.3–5.7). No consistent association was found between statin use and H. pylori therapy effectiveness. Therefore, the addition of statins to the usual H. pylori treatment cannot be currently recommended to improve cure rates.